Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon Dec 11, 2020 6:40pm
308 Views
Post# 32091373

RE:Shares and deals

RE:Shares and deals
Doccole wrote:

No question I am holding my shares right to the chest!

any comparables to a expected partnership out there?  It's easy if they sell the drug for 2b, then we know what to expect per share.  What about other deals? 


I don't know a lot about partnerships so any info is appreciated!  Bring 2021!



Good question Doccole.
As per Dan, we now have a 70% chance of a partnership.

Here's my guess ...
I would assume 3-4 partners in total ... one for Europe, one for USA, one for Japan and one for Rest-of-World (or something like that).
Upfront cash to cover P3 and some cash in the bank.
Royalties to be 10%-15%, depending on upfront cash outlay.
These partners may also have right of first refusal for future drugs.
Maybe a break fee should ATE choose to go a different route.
ATE to take this as a "floor" into discussions with Big Pharma.
Demand is high and one Big Pharma makes a bid for the full monty.

That's my guess ... could be 3-4 partners, might be one company to buy the first drug, might be an all-out acquisition to secure the future riches.  We should assume the first and hope for the third.
<< Previous
Bullboard Posts
Next >>